The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lex, A.
Right arrow Articles by Bessler, W. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lex, A.
Right arrow Articles by Bessler, W. G.

The Journal of Immunology, Vol 137, Issue 8 2676-2681, Copyright © 1986 by American Association of Immunologists

ARTICLES

A synthetic analogue of Escherichia coli lipoprotein, tripalmitoyl pentapeptide, constitutes a potent immune adjuvant

A Lex, KH Wiesmuller, G Jung and WG Bessler

Lipoprotein from the outer membrane of Escherichia coli and other Enterobacteriaceae constitutes a potent B lymphocyte mitogen and polyclonal activator in various species. Tripalmitoyl pentapeptide (S- (2,3-bis-(palmitoyloxy)-(2RS)-propyl)-N-palmitoyl-(R)-cysteinyl -(S)- seryl-(S)-seryl-(S)-asparaginyl-(S)-alanine) is a synthetic analogue of the N-terminal part of lipoprotein and has, in all assays tested, a biologic activity similar to native lipoprotein. It also exhibits a strong adjuvant activity in vitro: In the presence of 3.3 to 33.3 micrograms/ml of tripalmitoyl pentapeptide, the stimulation of the primary antibody response toward underivatized sheep red blood cells (SRBC) and toward trinitrophenylated (TNP-) SRBC was markedly enhanced, as measured by a direct hemolytic plaque assay. At optimal mitogen- and antigen-doses, plaque formation was increased up to 100-fold, and at suboptimal doses (0.03 to 0.3 microgram/ml) a 10- to 60-fold increase of plaque numbers was achieved. In the presence of tripalmitoyl pentapeptide, the antigen-specific IgM response was increased about sevenfold and the IgG response was augmented about 10-fold, as measured by ELISA. Similarly, in the secondary in vitro response to TNP-SRBC, a 7 to 10-fold enhancement of the antibody titer was obtained in the presence of the adjuvant. The application of tripalmitoyl pentapeptide and antigen had to occur concurrently in order to achieve a strong adjuvant effect. Addition of tripalmitoyl pentapeptide to the cell cultures 1 day after or 1 day before antigen application had no significant positive effect, and in several instances a decrease in antibody production was found. Thus, tripalmitoyl pentapeptide, a well- characterized synthetic product available in major amounts, constitutes a potent immune adjuvant for potential animal and clinical use.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. M. Calvo-Calle, G. A. Oliveira, and E. H. Nardin
Human CD4+ T Cells Induced by Synthetic Peptide Malaria Vaccine Are Comparable to Cells Elicited by Attenuated Plasmodium falciparum Sporozoites
J. Immunol., December 1, 2005; 175(11): 7575 - 7585.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. D. Fletcher, L. Bernfield, V. Barniak, J. E. Farley, A. Howell, M. Knauf, P. Ooi, R. P. Smith, P. Weise, M. Wetherell, et al.
Vaccine Potential of the Neisseria meningitidis 2086 Lipoprotein
Infect. Immun., April 1, 2004; 72(4): 2088 - 2100.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
T. U. Vogel, B. E. Beer, J. zur Megede, H.-G. Ihlenfeldt, G. Jung, S. Holzammer, D. I. Watkins, J. D. Altman, R. Kurth, and S. Norley
Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge
J. Gen. Virol., January 1, 2002; 83(1): 81 - 91.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
J. Cote-Sierra, A. Bredan, C. M. Toldos, B. Stijlemans, L. Brys, P. Cornelis, M. Segovia, P. de Baetselier, and H. Revets
Bacterial Lipoprotein-Based Vaccines Induce Tumor Necrosis Factor-Dependent Type 1 Protective Immunity against Leishmania major
Infect. Immun., January 1, 2002; 70(1): 240 - 248.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. H. Nardin, J. M. Calvo-Calle, G. A. Oliveira, R. S. Nussenzweig, M. Schneider, J.-M. Tiercy, L. Loutan, D. Hochstrasser, and K. Rose
A Totally Synthetic Polyoxime Malaria Vaccine Containing Plasmodium falciparum B Cell and Universal T Cell Epitopes Elicits Immune Responses in Volunteers of Diverse HLA Types
J. Immunol., January 1, 2001; 166(1): 481 - 489.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. G. Scragg, D. Kwiatkowski, V. Vidal, A. Reason, T. Paxton, M. Panico, A. Dell, and H. Morris
Structural Characterization of the Inflammatory Moiety of a Variable Major Lipoprotein of Borrelia recurrentis
J. Biol. Chem., January 14, 2000; 275(2): 937 - 941.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
G. Lowell, W. Ballou, L. Smith, R. Wirtz, W. Zollinger, and W. Hockmeyer
Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides
Science, May 6, 1988; 240(4853): 800 - 802.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1986 by The American Association of Immunologists, Inc. All rights reserved.